Document Detail

Treatment of bone metastasis induced by MDA-MB-231 breast cancer cells with an antibody against bone sialoprotein.
MedLine Citation:
PMID:  16465361     Owner:  NLM     Status:  MEDLINE    
The extracellular bone matrix protein bone sialoprotein (BSP) is considered to play an important role in the pathogenesis of lytic skeletal lesions which are associated with severe morbidity in breast, prostate or lung cancer patients. In addition to in vitro studies, nude rats were implanted with 10(5) MDA-MB-231 cells transfected with GFP into a small branch of the femoral artery. Osteolytic lesions of the respective hind leg were detected by X-ray and CT analysis as well as by immunohistochemistry. Exposure of MDA-MB-231GFP cells in vitro to an antibody against BSP (0-400 microg/ml) decreased proliferation, colony formation and migration of these cells by up to 95, 83 and 89 T/C%, respectively. In nude rats, pre-incubation of MDA-MB-231GFP cells prior to inoculation (25-100 microg/ml) reduced the mean osteolytic lesion size to 22 T/C% after 90 days of observation (p<0.05). Treatment of overt lytic metastasis with the anti-BSP antibody (10 mg/kg) resulted in a significantly smaller mean lesion size of 57 T/C% at the end of the observation period (p<0.05) as well as in new bone formation. Immunohistochemical analysis revealed the presence of BSP in MDA-MB-231GFP cells and in vessel endothelium cells during processes such as migration and invasion. In conclusion, an anti-BSP antibody decreased proliferation, colony formation and migration of MDA-MB-231GFP cells in vitro and reduced osteolysis besides inducing bone formation in a nude rat model.
Tobias Bäuerle; Jenny Peterschmitt; Heidegard Hilbig; Fabian Kiessling; Franz P Armbruster; Martin R Berger
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of oncology     Volume:  28     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2006 Mar 
Date Detail:
Created Date:  2006-02-08     Completed Date:  2006-03-28     Revised Date:  2010-02-04    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  573-83     Citation Subset:  IM    
Unit of Toxicology and Chemotherapy, Deutsches Krebsforschungszentrum Heidelberg, 69120 Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibodies, Monoclonal / immunology,  pharmacology,  therapeutic use*
Bone Neoplasms / drug therapy*,  secondary
Breast Neoplasms / drug therapy,  pathology
Cell Line, Tumor
Cell Movement / drug effects
Cell Proliferation / drug effects
Dose-Response Relationship, Drug
Green Fluorescent Proteins / genetics,  metabolism
Immunoglobulins / immunology,  pharmacology,  therapeutic use
Mammary Neoplasms, Experimental / drug therapy*,  pathology
Microscopy, Fluorescence
Rats, Nude
Sialoglycoproteins / immunology*
Time Factors
Tomography, X-Ray Computed
Tumor Stem Cell Assay
Xenograft Model Antitumor Assays / methods
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/IgY; 0/Immunoglobulins; 0/Sialoglycoproteins; 0/integrin-binding sialoprotein; 147336-22-9/Green Fluorescent Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  The cost of a rapid-test VCT clinic in South Africa.
Next Document:  Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced ...